NCT00703989View on ClinicalTrials.gov

Reactive Oxygen Species in the Pathogenesis of Diabetic Complications

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

February 29, 2008

Conditions
Type 1 Diabetes
Interventions
DIETARY_SUPPLEMENT

benfotiamine, α-lipoic acid

benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks

Trial Locations (1)

10461

GCRC, Albert Einstein College of Medicine, The Bronx

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

collaborator

National Institutes of Health (NIH)

NIH

lead

Albert Einstein College of Medicine

OTHER